Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Gain Therapeutics, Inc. (GANX) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Gain Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1819411.
Total stock buying since 2021: $24,544,441.
Total stock sales since 2021: $5,056.
Total stock option exercises since 2021: $38,716.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 111,400 | $201,004 | 0 | $0 | 20,212 | $0 |
| 2023 | 0 | $0 | 2,026 | $5,056 | 63,862 | $0 |
| 2022 | 18,738 | $24,343,437 | 0 | $0 | 0 | $0 |
| 2021 | 0 | $0 | 0 | $0 | 4,922 | $38,716 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-08 | 64,400 | $64,494 | 0 | $0 | 0 | $0 |
| 2024-07 | 17,000 | $20,740 | 0 | $0 | 0 | $0 |
| 2024-03 | 30,000 | $115,770 | 0 | $0 | 20,212 | $0 |
| 2023-12 | 0 | $0 | 2,026 | $5,056 | 637 | $0 |
| 2023-10 | 0 | $0 | 0 | $0 | 2,475 | $0 |
| 2023-09 | 0 | $0 | 0 | $0 | 57,450 | $0 |
| 2023-07 | 0 | $0 | 0 | $0 | 3,300 | $0 |
| 2022-05 | 18,738 | $24,343,437 | 0 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 0 | $0 | 4,922 | $38,716 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-08-09 | Mack Gene (CFO and Interim CEO) | Buy | 14,400 | 1.01 | 14,544 |
| 2024-08-09 | Islam Khalid (Executive Chairman) | Buy | 50,000 | 1.00 | 49,950 |
| 2024-07-01 | Richman Eric I | Buy | 17,000 | 1.22 | 20,740 |
| 2024-03-28 | Riley Jeffrey Scott | Buy | 30,000 | 3.86 | 115,770 |
| 2024-03-26 | Alder Matthias (Chief Executive Officer) | Option Ex | 20,212 | .00 | 0 |
| 2023-12-21 | Alder Matthias (Chief Executive Officer) | Sale | 206 | 2.46 | 506 |
| 2023-12-20 | Alder Matthias (Chief Executive Officer) | Option Ex | 637 | .00 | 0 |
| 2023-12-07 | Alder Matthias (Chief Executive Officer) | Sale | 1,820 | 2.50 | 4,550 |
| 2023-10-01 | Alder Matthias (Chief Executive Officer) | Option Ex | 1,650 | .00 | 0 |
| 2023-09-20 | Alder Matthias (Chief Executive Officer) | Option Ex | 2,550 | .00 | 0 |
| 2023-09-20 | Richman Eric I (Director) | Option Ex | 54,900 | .00 | 0 |
| 2023-07-01 | Alder Matthias (Chief Executive Officer) | Option Ex | 3,300 | .00 | 0 |
| 2022-05-25 | Richman Eric I (CHIEF EXECUTIVE OFFICER) | Buy | 2,482 | 2.58 | 6,403 |
| 2022-05-20 | Richman Eric I (CHIEF EXECUTIVE OFFICER) | Buy | 9,256 | 2.83 | 26,194 |
| 2022-05-19 | Calabrese Salvatore (CHIEF FINANCIAL OFFICER) | Buy | 3,000 | 8,100.00 | 24,300,000 |
| 2022-05-19 | Richman Eric I (CHIEF EXECUTIVE OFFICER) | Buy | 4,000 | 2.71 | 10,840 |
| 2021-08-16 | Richman Eric I | Option Ex | 4,922 | 7.87 | 38,716 |
Insider trading activities including stock purchases, stock sales, and option exercises of GANX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Gain Therapeutics, Inc. (symbol GANX, CIK number 1819411) see the Securities and Exchange Commission (SEC) website.